Legend Biotech Corporation (LEGN)Healthcare | Biotechnology | Somerset, United States | NasdaqGS
21.17 USD
+0.09
(0.427%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 21.13 -0.04 (-0.040%) ⇩ (April 17, 2026, 7:15 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:04 p.m. EDT
Legend Biotech (LEGN) appears to be in a state of uncertainty with mixed signals from fundamentals and options activity. While the stock has shown some recent rebounds, the negative profit margins, high debt-to-equity ratio, and negative return on equity suggest underlying financial challenges. The short-term price forecast indicates a potential decline, which could be a buying opportunity for short-term traders looking to capitalize on a dip. However, the long-term fundamentals are weak, and the lack of dividends makes it less appealing for dividend-focused investors. Overall, LEGN is a high-risk investment with limited upside potential and significant downside risks. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.043020 |
| AutoTheta | 0.161101 |
| MSTL | 0.298173 |
| AutoARIMA | 0.301635 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 76% |
| H-stat | 1.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.491 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 41.283 |
| Revenue per Share | 5.582 |
| Market Cap | 3,915,511,040 |
| Forward P/E | 18.41 |
| Beta | 0.08 |
| Profit Margins | -28.85% |
| Website | https://legendbiotech.com |
As of April 11, 2026, 3:04 p.m. EDT: Options activity indicates a mix of short-term and long-term speculation. The recent calls and puts show a concentration on out-of-the-money (OTM) strikes, suggesting some speculation on potential price increases, particularly for strikes above the current price. However, the high IV (implied volatility) on some OTM strikes suggests uncertainty or anticipation of significant price movements. The presence of ATM strikes with moderate volume and open interest suggests some traders are hedging or betting on minimal price movement. The overall options activity indicates a cautious outlook with some potential for upward movement but also significant volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.34615386 |
| Address1 | 2,101 Cottontail Lane |
| All Time High | 77.32 |
| All Time Low | 16.24 |
| Ask | 21.23 |
| Ask Size | 2 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 2,042,710 |
| Average Daily Volume3 Month | 2,178,049 |
| Average Volume | 2,178,049 |
| Average Volume10Days | 2,042,710 |
| Beta | 0.083 |
| Bid | 21.08 |
| Bid Size | 2 |
| Book Value | 5.418 |
| City | Somerset |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.17 |
| Current Ratio | 1.96 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 21.56 |
| Day Low | 20.8 |
| Debt To Equity | 41.283 |
| Display Name | Legend Biotech |
| Earnings Call Timestamp End | 1,773,144,000 |
| Earnings Call Timestamp Start | 1,773,144,000 |
| Earnings Timestamp | 1,773,145,800 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -127,100,000 |
| Ebitda Margins | -0.12353 |
| Enterprise To Ebitda | -57.4 |
| Enterprise To Revenue | 7.091 |
| Enterprise Value | 7,295,594,496 |
| Eps Current Year | 0.062 |
| Eps Forward | 1.15 |
| Eps Trailing Twelve Months | -1.62 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.3562 |
| Fifty Day Average Change | 2.8138008 |
| Fifty Day Average Change Percent | 0.15328886 |
| Fifty Two Week Change Percent | -34.615387 |
| Fifty Two Week High | 45.297 |
| Fifty Two Week High Change | -24.127 |
| Fifty Two Week High Change Percent | -0.53264016 |
| Fifty Two Week Low | 16.24 |
| Fifty Two Week Low Change | 4.9300003 |
| Fifty Two Week Low Change Percent | 0.30357146 |
| Fifty Two Week Range | 16.24 - 45.297 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,591,363,800,000 |
| Float Shares | 163,193,866 |
| Forward Eps | 1.15 |
| Forward P E | 18.408695 |
| Free Cashflow | -133,987,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,900 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.20031 |
| Gross Profits | 206,100,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01318 |
| Held Percent Institutions | 0.50708 |
| Implied Shares Outstanding | 184,955,648 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey. |
| Long Name | Legend Biotech Corporation |
| Market | us_market |
| Market Cap | 3,915,511,040 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_552805228 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -296,800,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,911,811,944 |
| Number Of Analyst Opinions | 16 |
| Open | 21.21 |
| Operating Cashflow | -100,200,000 |
| Operating Margins | -0.06724 |
| Payout Ratio | 0.0 |
| Phone | 737 317 5050 |
| Post Market Change | -0.040000916 |
| Post Market Change Percent | -0.18895094 |
| Post Market Price | 21.13 |
| Post Market Time | 1,776,467,755 |
| Previous Close | 21.08 |
| Price Eps Current Year | 341.45163 |
| Price Hint | 2 |
| Price To Book | 3.9073458 |
| Price To Sales Trailing12 Months | 3.8055313 |
| Profit Margins | -0.28846002 |
| Quick Ratio | 1.884 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.5625 |
| Region | US |
| Regular Market Change | 0.0900002 |
| Regular Market Change Percent | 0.426946 |
| Regular Market Day High | 21.56 |
| Regular Market Day Low | 20.8 |
| Regular Market Day Range | 20.8 - 21.56 |
| Regular Market Open | 21.21 |
| Regular Market Previous Close | 21.08 |
| Regular Market Price | 21.17 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,795,599 |
| Return On Assets | -0.05013 |
| Return On Equity | -0.2906 |
| Revenue Growth | 0.642 |
| Revenue Per Share | 5.582 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 184,955,648 |
| Shares Percent Shares Out | 0.1011 |
| Shares Short | 18,702,143 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 20,045,763 |
| Short Name | Legend Biotech Corporation |
| Short Percent Of Float | 0.2572 |
| Short Ratio | 13.55 |
| Source Interval | 15 |
| State | NJ |
| Symbol | LEGN |
| Target High Price | 86.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 57.235 |
| Target Median Price | 61.0 |
| Total Cash | 948,600,000 |
| Total Cash Per Share | 2.565 |
| Total Debt | 413,700,000 |
| Total Revenue | 1,028,899,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 27.83325 |
| Two Hundred Day Average Change | -6.66325 |
| Two Hundred Day Average Change Percent | -0.23939891 |
| Type Disp | Equity |
| Volume | 1,795,599 |
| Website | https://legendbiotech.com |
| Zip | 8,873 |